TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24607076

Group type: EXPERIMENTAL
Intervention: Toxic solution (ionic hydroxylamine hydrochloride at 9mg/ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hand dynamometer (no kinesiologist present)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Kinesiologist 1
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Kinesiologist 2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Kinesiologist 3
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gender comparison (female kinesiologists)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Belief in AK test effectiveness
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Time perception
Number of subjects: 51
Study: 22459183

Group type: EXPERIMENTAL
Intervention: 75°C CRF for 120 s to 180 s (SCRF group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 75°C CRF for 240 s to 300 s (LCRF group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 42°C PRF for 10 minutes followed by 75°C CRF for 120 s to 180 s (PCRF group)
Number of subjects: 60
Study: 19653815

Group type: EXPERIMENTAL
Intervention: Denosumab (30/120/180 mg every 4 weeks or 60/180 mg every 12 weeks)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 366

Group type: COMPARATOR
Intervention: IV BP
Number of subjects: 366
Study: 18404583

Group type: EXPERIMENTAL
Intervention: MIS approach (mini-midvastus approach)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (midvastus approach)
Number of subjects: 60
Study: 16094573

Group type: EXPERIMENTAL
Intervention: Creating a subperiosteal tunnel before lateral osteotomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Not creating a subperiosteal tunnel (Control)
Number of subjects: 18
Study: 12108909

Group type: EXPERIMENTAL
Intervention: Echocardiography (echo)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Radionuclide ventriculography (RNV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 70
Study: 10402691

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 76
Study: 8892171

Group type: EXPERIMENTAL
Intervention: Vitamin E (100 IU/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1538156

Group type: EXPERIMENTAL
Intervention: NG-mononmethyl-L-arginine (NMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arginase
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN-gamma stimulated mouse peritoneal macrophages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activated mouse macrophages
Number of subjects: 0
Study: 6339105

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31910496

Group type: EXPERIMENTAL
Intervention: UHR individuals with remission from the UHR state at 12-month follow-up (n=33, 36%)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Baseline functioning
Number of subjects: 146
Study: 30791824

Group type: EXPERIMENTAL
Intervention: Atosiban (37.5 mg total dose)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 30027297

Group type: EXPERIMENTAL
Intervention: Thao‐Child Health Program (TCHP) intervention
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Usual health care policy (Control)
Number of subjects: 2250
Study: 26822461

Group type: EXPERIMENTAL
Intervention: Supervised group exercise therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Home-based exercise therapy
Number of subjects: 102
Study: 24641549

Group type: EXPERIMENTAL
Intervention: Recognition heuristic applied by groups
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Time constraints
Number of subjects: 43
Study: 22472585

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289), 2/day for 6 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 62
Study: 19959243

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 6
Study: 17674398

Group type: EXPERIMENTAL
Intervention: FOCI Severity Scale
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: FOCI Symptom Checklist
Number of subjects: 113
Study: 15650887

Group type: COMPARATOR
Intervention: Pretension at 0% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pretension at 30% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pretension at 60% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pretension at 90% MVC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EMG activity (agonist and antagonist)
Number of subjects: 10
Study: 12404190

Group type: EXPERIMENTAL
Intervention: Sequential combined hormone‐replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d for 28 days and 5 mg of medroxyprogesterone acetate during the last 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10023944

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU, 5 MU, 10 MU for the first week, then 10 MU three times per week for 11 weeks)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (300 mg once daily for 12 weeks)
Number of subjects: 335
Study: 7775624

Group type: EXPERIMENTAL
Intervention: Local intraarterial infusion of 25 micrograms/h somatostatin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Systemic control infusion
Number of subjects: 6
Study: 1651741

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy followed by prophylactic cranial irradiation (PCI) for disease-free patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: N0 disease patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: N1 disease patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: N2 disease patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Patients receiving PCI
Number of subjects: 146
Study: 6130666

Group type: EXPERIMENTAL
Intervention: Continuation of beta-receptor blockers
Number of subjects: 48

Group type: COMPARATOR
Intervention: Withdrawal of beta-receptor blockers
Number of subjects: 48
Study: 31351829

Group type: EXPERIMENTAL
Intervention: Combined intervention program (9-session hands-on intervention)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study: 28983903

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound-guided short-axis needle tip navigation technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 102
Study: 27552592

Group type: EXPERIMENTAL
Intervention: Omega-3 supplements (1,470mg DHA and 147mg EPA daily for 12 weeks)
Number of subjects: 110
Study: 24393602

Group type: EXPERIMENTAL
Intervention: Secukinumab Early regimen (Weeks 0, 1, 2, 4)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Secukinumab Monthly regimen (Weeks 0, 4, 8)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 21526339

Group type: EXPERIMENTAL
Intervention: Compression leggings
Number of subjects: 12
Study: 19087000

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine
Number of subjects: 0
Study: 18004129

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/d for 1 week then 200 mg/d for 6 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 6 weeks)
Number of subjects: 73
Study: 15012923

Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Left Ventricular Opacification (LVO)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fundamental imaging
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: LVO with ECG-triggered Power Doppler
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 31
Study: 12468952

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sclerotherapy (n = 8)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Metoclopramide injection (n = 8)
Number of subjects: 26
Study: 9801509

Group type: EXPERIMENTAL
Intervention: Clinical Path for Coronary Artery Bypass Graft Patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 7698703

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 0
Study: 2535052

Group type: EXPERIMENTAL
Intervention: Fosenopril
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study: 380868

Group type: EXPERIMENTAL
Intervention: naproxen, 500 mg/day for 1 week
Number of subjects: 14

Group type: COMPARATOR
Intervention: diclofenac, 100 mg/day for 1 week
Number of subjects: 14
Study: 31101782

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 15 mg/kg/day for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 mg/day plus Vitamin C 500 mg/day for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no medical treatment)
Number of subjects: 0
Study: 28710212

Group type: EXPERIMENTAL
Intervention: 12-week internet intervention (Deprexis) plus usual care
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Care-as-usual alone (control)
Number of subjects: 1013
Study: 25329141

Group type: EXPERIMENTAL
Intervention: Massage focused on myofascial trigger points (MTrPs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (detuned ultrasound)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 56
Study: 23410808

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg monthly intravitreal injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photodynamic therapy (quarterly intravenous verteporfin coupled with PDT)
Number of subjects: 0
Study: 22494532

Group type: EXPERIMENTAL
Intervention: Soothing music for 45 min at nocturnal sleep time
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no music exposure)
Number of subjects: 50
Study: 19406542

Group type: EXPERIMENTAL
Intervention: Off-Pump Coronary Artery Bypass Surgery (OPCAB)
Number of subjects: 27806

Group type: COMPARATOR
Intervention: Conventional CAB (CAB)
Number of subjects: 27806
Study: 17550932

Group type: EXPERIMENTAL
Intervention: Aminoguanidine (iNOS inhibitor)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 16
Study: 15531222

Group type: EXPERIMENTAL
Intervention: Neurolytic coeliac plexus blockade (NCPB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bilateral splanchnic nerve blockade (SNB)
Number of subjects: 39
Study: 11797066

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 20
Study: 9492128

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (first injection)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (second injection)
Number of subjects: 50
Study: 7952396

Group type: EXPERIMENTAL
Intervention: Surgical limb perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3139830

Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg) after 30-day therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31768589

Group type: EXPERIMENTAL
Intervention: Daily TPTD (20-μg injection daily for 6 months)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Weekly TPTD (56.5-μg injection 1×/week for 6 months)
Number of subjects: 13
Study: 28687150

Group type: COMPARATOR
Intervention: Virtually optimized insoles (milled)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Virtually optimized insoles (printed)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Shape-based devices
Number of subjects: 20
Study: 26096691

Group type: EXPERIMENTAL
Intervention: Nicotine (6 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 23293012

Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 32
Study: 21226792

Group type: EXPERIMENTAL
Intervention: Diabetes screening intervention
Number of subjects: 3240
Study: 18433307

Group type: EXPERIMENTAL
Intervention: MRK adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine (3-dose regimen, doses ranging from 3 x 10^6 to 1 x 10^11 viral particles per 1-mL dose)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 17294878

Group type: EXPERIMENTAL
Intervention: Bicycle training (BT) with free choice of load parameters (FLC)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional hospital treatment
Number of subjects: 185
Study: 14611708

Group type: EXPERIMENTAL
Intervention: Levothyroxine (85.5 +/- 4.3 microg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 11938802

Group type: EXPERIMENTAL
Intervention: Chinese herbal treatment added during prednisone reduction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisone treatment (control group)
Number of subjects: 120
Study: 9104548

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 12 weeks
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 8478303

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg/day orally once daily for 10-14 days
Number of subjects: 173

Group type: COMPARATOR
Intervention: Erythromycin 1000 mg/day orally four times daily for 10-14 days
Number of subjects: 173
Study: 3522452

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study: 30051366

Group type: EXPERIMENTAL
Intervention: Surgical interventions for rectal cancer
Number of subjects: 130
Study: 26247163

Group type: EXPERIMENTAL
Intervention: Noxious Electrical Stimulation (NES)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eccentric Contractions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-Intensity Cycling
Number of subjects: 40
Study: 23837549

Group type: EXPERIMENTAL
Intervention: Constant Current (CC) stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Constant Voltage (CV) stimulation
Number of subjects: 30
Study: 23402179

Group type: EXPERIMENTAL
Intervention: Probiotic Bifiform (Bifidobacterium longum 10^7 and Enterococcus faecium 10^7) for 14 days
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 138
Study: 20581391

Group type: EXPERIMENTAL
Intervention: Sirolimus (target dose, 2 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 100
Study: 18766092

Group type: EXPERIMENTAL
Intervention: Real-time audiovisual feedback during the second and third trials
Number of subjects: 80

Group type: COMPARATOR
Intervention: Debriefing only (no feedback)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of feedback and debriefing
Number of subjects: 80
Study: 16389536

Group type: EXPERIMENTAL
Intervention: Audit and feedback + academic detailing
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Audit and feedback + seminar
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Audit and feedback alone
Number of subjects: 1800

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1800
Study: 12895205

Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 10848884

Group type: EXPERIMENTAL
Intervention: Insulin tolerance tests (ITT) performed during menstrual cycle phases in women
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin tolerance tests (ITT) performed in men
Number of subjects: 12
Study: 9112525

Group type: EXPERIMENTAL
Intervention: Thigh length pneumatic compression
Number of subjects: 90

Group type: COMPARATOR
Intervention: Calf length pneumatic compression
Number of subjects: 90
Study: 1549432

Group type: EXPERIMENTAL
Intervention: Auditory stimulus pulses audible (synchronization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory stimulus pulses turned off (continuation)
Number of subjects: 0
Study: 2581075

Group type: EXPERIMENTAL
Intervention: Timolol 30 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Timolol 60 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31783881

Group type: EXPERIMENTAL
Intervention: ΔSOFA score on day 7
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Mean SOFA score on day 1
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: 28-day mortality
Number of subjects: 647
Study: 28849703

Group type: EXPERIMENTAL
Intervention: Everyday Memory Questionnaire (EMQ)
Number of subjects: 169
Study: 27085221

Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler (OD) monitoring
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard parameters (Standard group)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 25076013

Group type: EXPERIMENTAL
Intervention: 200mg quercetin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400mg quercetin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quercetin and isorhamnetin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Q3GA
Number of subjects: 15
Study: 22646692

Group type: EXPERIMENTAL
Intervention: Geriatric syndrome complications (≥ 2 complications)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Geriatric syndrome complications (one complication)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Geriatric syndrome complications (no complications)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Unresolved geriatric syndrome complications
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Resolved geriatric syndrome complications
Number of subjects: 350
Study: 20205025

Group type: EXPERIMENTAL
Intervention: Health promotion campaigns targeting Theory of Reasoned Action (TRA)‐based predictors of condom use
Number of subjects: 756
Study: 17604555

Group type: EXPERIMENTAL
Intervention: Music listening (specific music tasks)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Music of Nolwenn Leroy
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Music listening tasks
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (no music listening)
Number of subjects: 266
Study: 15207544

Group type: EXPERIMENTAL
Intervention: Amphiphilogels
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% sodium lauryl sulphate (SLS) solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aqueous Cream BP
Number of subjects: 0
Study: 11794914

Group type: EXPERIMENTAL
Intervention: Ambulatory management for GDM
Number of subjects: 681

Group type: COMPARATOR
Intervention: Hospitalization for GDM
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Ambulatory management for PGDM
Number of subjects: 681

Group type: COMPARATOR
Intervention: Hospitalization for PGDM
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Ambulatory management
Number of subjects: 681

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 681
Study: 9919007

Group type: EXPERIMENTAL
Intervention: HCV positive patients (22 out of 55, 40%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: ELISA for HCV detection
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: RT‐PCR for HCV detection
Number of subjects: 55
Study: 8042098

Group type: EXPERIMENTAL
Intervention: More expensive nebulisers (Eolo, Pharmoneb, Pari)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cheaper nebulisers (Simba, New Constellation, Ariette)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All nebuliser models
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nebulisers (various models)
Number of subjects: 6
Study: 3051071

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Baseline MAO activity
Number of subjects: 62
Study: 31221002

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 37
Study: 27461413

Group type: EXPERIMENTAL
Intervention: Continuum messages
Number of subjects: 598

Group type: COMPARATOR
Intervention: Categorical messages
Number of subjects: 598

Group type: COMPARATOR
Intervention: Neutral control messages
Number of subjects: 598
Study: 26133711

Group type: EXPERIMENTAL
Intervention: 1 µg/kg of DEX
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 80
Study: 23475383

Group type: EXPERIMENTAL
Intervention: Saccadic tasks with head restrained or free to move
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Head-free condition
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 5
Study: 21772315

Group type: EXPERIMENTAL
Intervention: Caffeine in sugar-sweetened beverages (SSBs)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Removal of caffeine from SSBs
Number of subjects: 93
Study: 19164403

Group type: EXPERIMENTAL
Intervention: Hospital exercise programme
Number of subjects: 32

Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of hospital vs home exercise programme
Number of subjects: 32
Study: 16618363

Group type: EXPERIMENTAL
Intervention: Prebiotic formula (0.6 g GOS/FOS/100 ml)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Probiotic formula (6.0 x 10^9 cfu Bifidobacterium animalis/100 ml)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 57
Study: 14744166

Group type: EXPERIMENTAL
Intervention: Paroxetine 60 mg/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Venlafaxine 300 mg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Switch to alternate SRI (either paroxetine or venlafaxine) after 4-week tapering phase
Number of subjects: 150